Natalia Pasierb

Natalia Pasierb

Auto-generated profile, based on publicly available information

Natalia Pasierb

Military Medical Institute – National Research Institute in Warsaw, ul. Szaserów 128, 04-141 Warszawa, Poland

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 July 2025 in Archiv Euromedica
Verified
Journal Article
Closed access
ARAneta Rasińska
Aneta Rasińska
JJJustyna Jachimczak
Justyna Jachimczak
PRPiotr Rzyczniok
Piotr Rzyczniok
PBPaulina Bala
Paulina Bala
JMJustyna Matusik
Justyna Matusik
MKMateusz Kopczyński
Mateusz Kopczyński
Ackground: Delayed-onset muscle soreness (DOMS) is a common consequence of eccentric exercise, often impairing recovery and performance. Omega-3 polyunsaturated fatty acids (PUFAs), particularly EPA and DHA, have been proposed as potential nutritional interventions to mitigate DOMS through anti-inflammatory and membrane-stabilizing mechanisms. Methods: A structured literature search of PubMed, Scopus, and Web of Science (2000–2024) identified 14 randomized controlled trials and clinical studies investigating the effects of omega-3 supplementation on DOMS and exercise-induced muscle damage (EIMD). Results: Most studies used daily doses of 1.8–3 g of combined EPA/DHA for at least 3–4 weeks. Findings suggest that omega-3 supplementation may reduce perceived muscle soreness 24–72 hours post-exercise and exert mild anti-inflammatory effects. However, heterogeneity in study design, dosage, duration, and outcome measures limits the comparability and generalizability of results. Conclusion: Omega-3 fatty acids may offer a modest adjunctive benefit in reducing DOMS and supporting recovery. Further well-controlled trials are needed to clarify dose–response relationships and population-specific effects.

29 September 2025 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
PDF file
SKSebastian Kupisiak
Sebastian Kupisiak
ARAneta Rostkowska
Aneta Rostkowska
MDMalwina Draim
Malwina Draim
NPNatalia Pasierb
Natalia Pasierb
MKMichalina Kosowska
Michalina Kosowska
KTKacper Trząsalski
Kacper Trząsalski
Introduction and Purpose: Myopia is currently the most prevalent refractive error worldwide, with a rapidly increasing incidence, particularly among children and adolescents in urbanized regions. This review outlines the most effective evidence-based strategies for preventing and slowing the progression of myopia, with a focus on both pharmacological and non-pharmacological approaches. The State of Knowledge: Recent studies have highlighted that increased time spent outdoors significantly reduces the onset of myopia in non-myopic children, though its effect on progression in already myopic individuals appears limited. Light exposure, especially to moderate-intensity natural light, has shown potential in mitigating axial elongation and promoting choroidal thickening. Sleep quality and duration may also influence myopia development, though further research is needed to confirm this relationship. Pharmacological intervention with low-dose atropine (particularly 0.01–0.05%) is currently the most effective and widely accepted treatment, offering substantial benefits with minimal side effects. Optical interventions such as orthokeratology, multifocal spectacle lenses, and dual-focus contact lenses have demonstrated efficacy in controlling axial elongation by modifying peripheral retinal defocus. Summary: Combining lifestyle modifications (outdoor activity and light exposure) with pharmacological (low-dose atropine) and optical (e.g., orthokeratology and bifocal lenses) interventions provides a comprehensive, multimodal strategy to manage and slow myopia progression. Early implementation of such interventions is essential in addressing the growing public health burden of myopia.

12 July 2025 in Quality in Sport
Verified
Journal Article
Open access
PDF file
PRPiotr Rzyczniok
Piotr Rzyczniok
ARAneta Rasińska
Aneta Rasińska
WRWeronika Rasińska
Weronika Rasińska
ARAnna Rzyczniok
Anna Rzyczniok
JMJustyna Matusik
Justyna Matusik
MKMateusz Kopczyński
Mateusz Kopczyński
The influence of infectious diseases on the development of infertility continues to be an area of active research. This review explores how the microbial environment within the male reproductive system may contribute to infertility. It examines how certain pathogenic characteristics of microorganisms can lead to reproductive issues when inflammation occurs in the male urogenital tract, focusing on how such infections impact sperm quality - such as reducing sperm count, impairing motility, altering morphology, and diminishing fertilization potential. Additionally, the review addresses how the body’s immune response and its resistance mechanisms may play a role in sustaining chronic inflammation in male reproductive organs. Purpose: To delineate how specific microbial communities and pathogen-linked virulence traits contribute to male infertility by disrupting spermatogenesis, sperm function and local immune homeostasis in the urogenital tract. Material and Methods: Narrative literature review based on a systematic search of microbiology, andrology and urology studies that compared semen microbiota, immune markers and clinical outcomes between proven-fertile and infertile men; key in-vitro and animal mechanistic papers were also appraised to integrate pathophysiological insights. Findings: Infertile semen shows a reproducible shift from protective Gram-positive Lactobacillus/Corynebacterium spp. to opportunistic Escherichia coli, Gardnerella, anaerobic Bacteroides and coagulase-negative staphylococci. Uropathogenic E. coli fimbriae, toxins and stress proteins, high anti-lysozyme staphylococci and Chlamydia/Ureaplasma lipopolysaccharides induce sperm agglutination, oxidative DNA damage and apoptosis. Declines in seminal lysozyme, lactoferrin and zinc - particularly in chronic prostatitis or hyper-viscous semen - halve bactericidal capacity, allowing chronic inflammation to persist.

4 May 2025 in Quality in Sport
Verified
Journal Article
Open access
PDF file
ARAneta Rasińska
Aneta Rasińska
PRPiotr Rzyczniok
Piotr Rzyczniok
ARAnna Rzyczniok
Anna Rzyczniok
WRWeronika Rasińska
Weronika Rasińska
JJJustyna Jachimczak
Justyna Jachimczak
JMJustyna Matusik
Justyna Matusik
Lung cancer has, for several decades, been the second most frequently diagnosed malignancy and the leading cause of cancer death worldwide. It continues to pose a significant burden on healthcare systems and a serious challenge for clinicians and patients. The majority of patients present with advanced disease at diagnosis, and most survive less than five years. Although novel targeted therapies have been introduced in recent years, there remains a significant demand for treatments capable of improving response and prolonging survival while having minimal impact on quality of life. Recent clinical evidence supporting immunotherapeutic approaches indicates that they may represent the next major therapeutic breakthrough in lung cancer management. Non-small cell lung cancer (NSCLC), which accounts for about 85% of lung cancers, was once considered a non-immunogenic disease; yet, as with several other malignancies, emerging data suggest that in most cases, the lack of immune response is functional and can be therapeutically overcome. Purpose: To provide a comprehensive review of immunotherapy as an innovative therapeutic approach for non-small cell lung cancer (NSCLC), highlighting the role of key immune mechanisms and checkpoint inhibitors. Material and Methods: The authors conducted a detailed literature review examining the immune context of NSCLC, discussing the significance of PD-1/PD-L1 and CTLA-4 checkpoints, relevant clinical trials, and emerging biomarkers like PD-L1 expression and tumor mutational burden. Findings: Immunotherapy, particularly PD-1/PD-L1 inhibitors, substantially improves survival in advanced NSCLC and can be enhanced by combination strategies. Biomarkers help identify patients most likely to benefit while guiding treatment choices.

18 September 2025 in Pediatria i Medycyna Rodzinna
Verified
Journal Article
Open access
MMMagdalena Mosakowska
Magdalena Mosakowska
NPNatalia Aleksandra Pasierb
Natalia Aleksandra Pasierb
MKMichalina Faustyna Kosowska
Michalina Faustyna Kosowska
BRBarbara Teresa Rękas
Barbara Teresa Rękas
WDWiktoria Dzierzgowska
Wiktoria Dzierzgowska
Stanisław NiemczykStanisław Niemczyk
Stanisław Niemczyk
Objective: Vasculitis is an increasingly prevalent condition, often characterised by an insidious and multifaceted clinical course, which delays accurate diagnosis and treatment. Case Report: A 63-year-old male diagnosed with granulomatosis with polyangiitis (GPA), who demonstrated pulmonary disease progression after six months of remission-induction therapy with cyclophosphamide. Imaging studies revealed new cavitating infiltrates in the upper lobe of the left lung, along with numerous satellite nodules in both lungs. A thorough differential diagnosis ruled out infectious aetiologies. Conclusions: Despite extensive diagnostic efforts, including invasive procedures and positron emission tomography–computed tomography scanning, exclusion of malignancy remained challenging. Establishing an accurate diagnosis and excluding infectious or neoplastic diseases enables timely and appropriate treatment, which can be life-saving in patients with GPA. Delayed treatment increases the risk of GPA-related organ complications.

4 May 2025 in Quality in Sport
Verified
Journal Article
Open access
PDF file
PRPiotr Rzyczniok
Piotr Rzyczniok
ARAneta Rasińska
Aneta Rasińska
WRWeronika Rasińska
Weronika Rasińska
ARAnna Rzyczniok
Anna Rzyczniok
JMJustyna Matusik
Justyna Matusik
JJJustyna Jachimczak
Justyna Jachimczak
Lipid disorders stem from imbalances in the levels of cholesterol, low-density lipoproteins (LDL), high-density lipoproteins (HDL), and triglycerides (TG). Among Polish adults over the age of 18, these conditions may affect as many as 60–80% of individuals. Such high prevalence is closely linked to the occurrence of cardiovascular diseases, for which dyslipidemias serve as a key contributing factor. Unfortunately, these disorders are also the leading cause of premature death in Poland. Consequently, the appropriate management of blood lipid concentrations—through both well-selected pharmacotherapy and supportive non-pharmacological measures—plays a vital role in reducing related risks. The primary class of lipid-lowering drugs comprises 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors, commonly known as statins. Their principal mechanism involves lowering LDL-C to levels commensurate with the patient’s cardiovascular risk profile. Should these targets remain unmet, additional agents can be employed, such as ezetimibe in conjunction with statins, or a newer group of lipid-lowering medications known as PCSK9 inhibitors, used either as monotherapy or in combination. These drugs are monoclonal antibodies directed against proprotein convertase subtilisin/kexin type 9 (PCSK9). Purpose: This paper briefly examines the role of PCSK9 inhibitors in managing dyslipidemia and their impact on reducing LDL cholesterol and preventing cardiovascular events. Material and Methods: We reviewed available literature, clinical trials, and guidelines on PCSK9 biology and the effectiveness and safety of PCSK9 inhibitors compared to other lipid-lowering therapies. Findings: PCSK9 inhibitors (alirocumab, evolocumab) can lower LDL-C by up to 60%. They can be used alone or with statins/ezetimibe, offer a favorable safety profile, and significantly reduce cardiovascular risk.